Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · IEX Real-Time Price · USD
109.01
+0.17 (0.16%)
At close: Jul 19, 2024, 4:00 PM
109.06
+0.05 (0.05%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Jazz Pharmaceuticals Revenue
Jazz Pharmaceuticals had revenue of $3.84B in the twelve months ending March 31, 2024, with 2.81% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $901.98M with 1.03% year-over-year growth. In the year 2023, Jazz Pharmaceuticals had annual revenue of $3.83B with 4.78% growth.
Revenue (ttm)
$3.84B
Revenue Growth
+2.81%
P/S Ratio
1.79
Revenue / Employee
$1,372,634
Employees
2,800
Market Cap
6.87B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 3.83B | 174.83M | 4.78% |
Dec 31, 2022 | 3.66B | 565.14M | 18.26% |
Dec 31, 2021 | 3.09B | 730.67M | 30.91% |
Dec 31, 2020 | 2.36B | 201.81M | 9.34% |
Dec 31, 2019 | 2.16B | 270.84M | 14.32% |
Dec 31, 2018 | 1.89B | 272.23M | 16.82% |
Dec 31, 2017 | 1.62B | 130.72M | 8.79% |
Dec 31, 2016 | 1.49B | 163.17M | 12.32% |
Dec 31, 2015 | 1.32B | 151.93M | 12.95% |
Dec 31, 2014 | 1.17B | 300.45M | 34.44% |
Dec 31, 2013 | 872.42M | 286.44M | 48.88% |
Dec 31, 2012 | 585.98M | 313.70M | 115.21% |
Dec 31, 2011 | 272.28M | 98.50M | 56.68% |
Dec 31, 2010 | 173.78M | 45.33M | 35.29% |
Dec 31, 2009 | 128.45M | 60.94M | 90.26% |
Dec 31, 2008 | 67.51M | 2.21M | 3.39% |
Dec 31, 2007 | 65.30M | 20.45M | 45.58% |
Dec 31, 2006 | 44.86M | 23.41M | 109.20% |
Dec 31, 2005 | 21.44M | - | - |
Dec 31, 2004 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Grifols | 7.32B |
Exelixis | 1.85B |
Penumbra | 1.10B |
HealthEquity | 1.04B |
Halozyme Therapeutics | 862.99M |
Ionis Pharmaceuticals | 776.62M |
Repligen | 607.45M |
Tempus AI | 562.02M |
JAZZ News
- 5 minutes ago - Jazz Pharmaceuticals Announces Successful Completion of Term Loan Repricing and Irrevocable Election of Settlement Method for the 2.000% Exchangeable Senior Notes due 2026 - PRNewsWire
- 4 days ago - Jazz Pharmaceuticals to Report 2024 Second Quarter Financial Results on July 31, 2024 - PRNewsWire
- 13 days ago - Jazz Pharmaceuticals Promotes Samantha Pearce to Chief Commercial Officer - PRNewsWire
- 4 weeks ago - Why Is Jazz Pharmaceuticals Stock Trading Lower On Thursday? - Benzinga
- 4 weeks ago - Jazz Pharmaceuticals' tremor drug fails to meet main goal in mid-stage study - Reuters
- 4 weeks ago - Jazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor - PRNewsWire
- 7 weeks ago - Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024 - PRNewsWire
- 7 weeks ago - Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024 - PRNewsWire